CA-GSD/ANANDA
23.3.2021 16:02:07 CET | Business Wire | Press release
POSITIVE ALL THE WAY , an award-winning documentary about the Paralympics is now available internationally through Ananda Media. The short documentary, produced by The Foundation for Global Sports Development (GSD) and Sidewinder Films, won “Best Documentary” at the Together! 2020 Disability Film Festival .
With personal interviews and captivating footage, POSITIVE ALL THE WAY celebrates the power of adaptive sport to ignite the human spirit. The film chronicles the growth of the Paralympics under the leadership of Sir Philip Craven, who served as the President of the International Paralympic Committee from 2001 through 2017. Staying true to the integrity of sport and his personal principles, Sir Philip led the sports organization through moments of crisis – such as funding shortfalls and the 2016 Russian doping scandal - while positioning the Paralympics as a leading sports organization.
"Ever since I first met Steven Ungerleider and David Ulich in 2011, I very quickly realized that the true spirit of sport is embodied in everything that The Foundation for Global Sports Development and Sidewinder Films undertakes,” said Sir Philip Craven, who is featured in the film. “In my work with the International Paralympic Committee, I tried to follow that principle and to also follow very closely the vision of the IPC which was ’to enable Para athletes to achieve sporting excellence and inspire and excite the world.’ This is what I believe Sidewinder Films portrays in POSITIVE ALL THE WAY , and I am so pleased that they have partnered with Ananda Media in order that many more people can experience the true spirit of sport!”
"The Paralympic movement reaches across the globe and plays a remarkable role in promoting inclusion worldwide,” said David Ulich, director and producer of the film. “We are delighted to partner with Ananda Media to bring POSITIVE ALL THE WAY to international audiences who can join this movement.”
Dr. Steven Ungerleider, director and producer of POSITIVE ALL THE WAY, agreed. “Sport has the power to change the world, and we are passionate about telling those stories through film. Working with Ananda Media is a perfect fit, and we are honored to have our documentary featured alongside other compelling sports films.”
Ananda Media is a French-based distributor of adventure sports, travel, and healthy lifestyle content. Much of their content, including POSITIVE ALL THE WAY , is available on-demand for worldwide audiences. Visit http://anandamedia.net to learn more.
About Ananda Media
Ananda Media is a producer and distributor of action sports and adventure travel programming for television and digital media. We pride ourselves on working with the top independent film-makers, and TV Channels in order to ensure that our content offering is both unparalleled and broadcast, streamed or downloaded to millions around the world.
More info: http://anandamedia.net
About The Foundation for Global Sports Development and Sidewinder Films
The Foundation for Global Sports Development, established in 1996, was born out of a desire to promote and protect the best parts of sport. Guided by its original mission, the foundation delivers and supports initiatives that promote accessible, fair, and abuse-free sport for youth. The foundation achieves this objective through grants, awards, educational projects, and filmmaking. In 2015, the foundation launched its media company, Sidewinder Films, to inspire and educate audiences through films that shed light on the remarkable, untold stories that celebrate the sport of life. Visit www.globalsportsdevelopment.org and www.sidewinderfilms.org to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005297/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom